Cerebrolysin Peptide Fraction
Also known as: CNTF-derived fragments, NAP/Davunetide relationship
Overview
Individual peptide fractions within Cerebrolysin preparation include components that mimic BDNF, GDNF, NGF, and CNTF activity. Research has identified specific small peptide sequences within the preparation responsible for distinct neuroprotective activities, including fragments that activate neurotrophic factor receptors TrkA, TrkB, and GFRα1-4. Understanding these individual fractions has guided development of targeted synthetic analogs including Davunetide (NAP) which was derived from the ADNP-related neuroprotective activity associated with VIP-stimulated neuroprotection.
Mechanism of Action
Individual fractions within Cerebrolysin activate different neurotrophic factor receptors: BDNF-like peptides activate TrkB; NGF-like peptides activate TrkA (p75NTR); GDNF-mimetics activate RET/GFRα receptor complex; CNTF-mimetics activate the tripartite CNTFR/LIFR/gp130 complex. The combination of simultaneous activity at multiple neurotrophic signaling nodes produces synergistic neuroprotective effects exceeding what any single neurotrophic factor can achieve.
Potential Benefits
- Simultaneous activation of multiple neurotrophic factor pathways
- Synergistic neuroprotection exceeding single-factor approaches
- BBB-penetrant delivery of neurotrophic activity
- Guides development of next-generation targeted neuropeptides
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 5 mL IM daily for 10 days |
| Intermediate | 10 mL IM or slow IV daily for 20 days |
| Advanced | 20-30 mL IV infusion daily for 20 days (stroke recovery) |
| Cycle Duration | 10-20 day courses, repeat 2-4x yearly |
Clinical administration only — typically hospital/clinic-based IV. Contains low-molecular-weight neuropeptides from porcine brain.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intramuscular Injection High
Standard outpatient route (5-10 mL).
Slow Intravenous Infusion 100%
For higher doses (20-30 mL) — diluted in saline, infused over 15-60 min.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Cerebrolysin Peptide Fraction:
Stroke Recovery Protocol
European stroke rehabilitation combination — Cerebrolysin for trophic support, Semax for BDNF, Citicoline for membrane phospholipid support.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store at room temperature <25°C, protected from light. Do not freeze. |
|---|
No reconstitution required. For IV use, dilute in 0.9% saline, 5% glucose, or Ringer's solution.
Need exact syringe measurements?
Amino Acid Sequence
Complex mixture of <10 kDa peptides; individual fractions being characterized
Side Effects & Safety
- As Cerebrolysin: see parent compound
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Cerebrolysin Peptide Fraction for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.